1 / 11

Infantile spasm treatment market analysis| Coherent Market Insights

Read here the latest updates on the Infantile spasm treatment market analysis published by the CMI team.

adwaitcoherent
Download Presentation

Infantile spasm treatment market analysis| Coherent Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Marketing Insights https://www.coherentmarketinsights.com/ Market Research & Business Consulting Services Covid-19 Impact Tracker

  2. INFANTILE SPASM TREATMENT MARKET ANALYSIS Infantile Spasm Treatment Market, by Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), by Route of Administration (Oral and Parenteral), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026 Infantile spasm treatment play a major role in modern healthcare, as they are used for the treatment of seizures of an epilepsy syndrome in infants usually below 1 year. The global infantile spasm treatment market size was valued at US$ 111.1 million in 2017 and is expected to exhibit a CAGR of 3.1% over the forecast period (2018 – 2026).

  3. Figure 1. Global Infantile Spasm Treatment Market Value (US$ Mn), by Region, 2017

  4. Increasing government initiatives for treatment of rare diseases is expected to propel growth of the infantile spasm treatment market Infantile spasm, also called as west syndrome, is a rare disorder that affects children below 1 year age. Seizures in children often appear as normal hiccups or body movement, and parents are unaware about the presence of this disease in their kid. Therefore, to tackle this challenge, various governments and organizations are initiating programs to educate people about the disease. The government of China published a comprehensive list of rare diseases in 2018, in order to better identify the patients affected by rare disease and provide treatment for the same. Moreover, such initiatives will help to speed up the drug development process for rare diseases. Increasing birth rate could result in high prevalence of infantile spasm, which is expected to drive growth of the infantile spasms treatment market over the forecast period. However, high cost of treatment, lack of proper diagnosis of infantile spasm, and stringent regulations for drug approval are some of the factors hindering the market growth. For instance, Acthar, which is a corticotropin branded product from Mallinckrodt pharmaceutical, costs around US$ 125,000 per patient, i.e. US$ 28,000 per dose

  5. Figure 2. Global Infantile Spasm Treatment Market Share (%), by Product Type, 2018 and 2026

  6. Increasing adoption of infantile spasms treatment procedure in North America is expected to bolster the market growth North America holds dominant position in the global infantile spasm treatment market, owing to high adoption of infantile spasms treatment procedures and large scale research and development activities in this region. For instance, INSYS Therapeutics developed Cannabidiol in October 2012, Oral Solution for infantile spasm, which is under phase III clinical trial. The reoccurrence of infantile spasm is a major factor that boosts the market growth. Increasing prevalence of central nervous system (CNS) infection can develop infantile spasm which in turn is expected to boost the market growth. In July 2012, the National Center for Biotechnology Information (NCBI) report stated that around 50% of infantile spasm cases in the U.S. have a prenatal cause, including central nervous system infection, intrauterine insults, neurologic disorders such as tuberous sclerosis complex (TSC), and genetic syndrome. Moreover, approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) that helps in speedy approval by designating the orphan drug status to drugs targeted to benefit patients with rare disease is expected to boost the market growth.

  7. Key Players Major players operating in the global infantile spasm market include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics, Inc., and Anavex Life Sciences Corp.

  8. Request Sample Report Request Customization Download PDF Brochure Talk to Analyst Referance: https://www.coherentmarketinsights.com/market-insight/infantile-spasm-treatment-market-2453

  9. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. What We Provide:Customized Market Research AnalysisIndustry Analysis ServicesBusiness Consulting ServicesLong Term Engagement ModelCountry Specific Analysis

  10. Contact Us Mr. Shah Coherent Market Insights Pvt. LTD.Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S.Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  11. Thank You Kindly Follow CMI Social Media Profiles for the latest Company Updates. Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related